FDA Expands Test for Gastric and Esophageal Cancers - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Test for Gastric and Esophageal Cancers

  • by Kathryn Wighton

  • July 14, 2026

Related Content

Neurogenic progression may falter in MDD

Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.

Medical Oddities: Dogs share our mortality markers

The bond with dogs runs deeper, the brain enjoys a good sweat, love on screen gets real, and tea carries a little more weight.

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.